Delhi HC Permits Zydus to Sell Cancer Drug Biosimilar
Delhi High Court permits Zydus Lifesciences to sell its biosimilar of cancer drug Nivolumab until patent expiry in May 2026. Court mandates detailed sales records to protect innovator Squibb's interests. Read more.